HighVista Strategies’s Centessa Pharmaceuticals CNTA Stock Holding History

HighVista Strategies’s Portfolio CNTA Stock Details CNTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-5,964	Closed	-$237K	–	157
2026 Q1	$237K	Sell	5,964 -38,526	-87%	-$985K	0.07%	156
2025 Q4	$1.11M	Sell	44,490 -18,811	-30%	-$476K	0.29%	101
2025 Q3	$1.54M	Buy	63,301 +22,617	+56%	+$402K	0.38%	80
2025 Q2	$535K	Buy	40,684 +1,664	+4%	+$21.1K	0.2%	122
2025 Q1	$561K	Sell	39,020 -7,096	-15%	-$116K	0.22%	123
2024 Q4	$772K	Hold	46,116	–	–	0.29%	110
2024 Q3	$737K	Buy	+46,116	New	+$565K	0.25%	107

HighVista Strategies's CNTA Position: Q2 2026 in Review

HighVista Strategies sold out of Centessa Pharmaceuticals (CNTA) in Q2 2026, closing a stake of 5,964 shares — an estimated $237K sold.

HighVista Strategies first reported a position in CNTA in Q3 2024 and held it in 7 quarters. The position peaked at $1.54M in Q3 2025. 0 funds tracked by Wall St. Rank hold CNTA as of Q2 2026.

HighVista Strategies reported no remaining Centessa Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
HighVista Strategies sold 5,964 Centessa Pharmaceuticals shares in Q2 2026, an estimated $237K.
HighVista Strategies first reported a position in Centessa Pharmaceuticals in Q3 2024 and held it in 7 quarters.
HighVista Strategies's Centessa Pharmaceuticals position peaked at $1.54M in Q3 2025.
0 funds tracked by Wall St. Rank held Centessa Pharmaceuticals as of Q2 2026.

Based on HighVista Strategies's 13F filing for Q2 2026, filed 14 Aug 2026.